

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Clinical trial on the effect of hyperthyroidism treatment on serum prolactine level in female hyperthyroidism patients of pregnancy age (15-50 y)

Protocol summary

Summary

Objectives: The objective of this study is evaluating the effect of hyperthyroidism treatment on serum prolactine level. **Design:** This study is a pre-test, post-test one and the level of serum prolactine is measured in hyperthyroidism patients pre and post intervention. **Setting and Conduct:** Hyperthyroidism patients which were eligible to participate in the study will be treated and their serum prolactine level is measured before and after treatment. **Participants:** Female hyperthyroidism patients aged 15-50 years whom do not use any pharmaceutical agent which increases prolactine level. **Interventions:** Administering anti-hyperthyroidism agents. **Main outcomes:** Serum prolactine level

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201207191774N4**
Registration date: **2012-12-30, 1391/10/10**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-12-30, 1391/10/10

Registrant information

Name

Mojgan Sanjari

Name of organization / entity

Kerman University of Medical Science

Country

Iran (Islamic Republic of)

Phone

+98 34 1322 2506

Email address

msanjari@kmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Kerman, Vice chancellor for Research and Technology of University of Medical Sciences, Tahmasb Abad crossroads, the begining of Jahad Boulevard, the begining of Ebn-e-Sina street, In front of Besat clinic

Expected recruitment start date

2012-03-20, 1391/01/01

Expected recruitment end date

2013-05-22, 1392/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Clinical trial on the effect of hyperthyroidism treatment on serum prolactine level in female hyperthyroidism patients of pregnancy age (15-50 y)

Public title

Study of serum prolactin level in women with Hyperthyroidism

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Women with hyperthyroidism; Age between 15 to 50 years Exclusion criteria : use of drugs which increase prolactine level: dopamine receptor blocker including phenotiazine, chlorpromazin, perfenazine, butirofenon, halo peridole, thioxantine, metocloperamide ; dopamin synthesis inhibitor (etc. methyl dopa) ; cathecolamin

releasing agent: reserpin; Opiates ;H2 blockers including cimetidin,ranitidin; Imipramin,Amitriptylin; serotonin intake inhibitor:Fluoxetine; Calcium channel blockers:Verapamil; hormones: Estrogens;Antiandrogens,TRH; Others:pregnancy,lactation,liver disease,chronic kidney disease.

Age

From **15 years** old to **50 years** old

Gender

Female

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **160**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee Vice chancellor for Research and Technology of kerman university of medical scienc

Street address

Kerman, Vice chancellor for Research and Technology of University of Medical Sciences, Tahmasb Abad crossroads, the beginning of Jihad Boulevard, the begining of Ebn-e-Sina street, In front of Besat clinic

City

Kerman

Postal code

7619813159

Approval date

2012-08-23, 1391/06/02

Ethics committee reference number

91193

Health conditions studied

1

Description of health condition studied

hyperthyroidism

ICD-10 code

E05.9

ICD-10 code description

Hyperthyroidism NOS

Primary outcomes

1

Description

serum prolactine level

Timepoint

Pre-treatment; post-treatment

Method of measurement

ICMA

Secondary outcomes

empty

Intervention groups

1

Description

methimazole (20mg) is administered to the patients for 2 months.

Category

Treatment - Drugs

2

Description

in this study, primary serum level of prolactine before the initiation of metimazole administration is considered as the control value. no drug/placebo group is defined for this study.

Category

N/A

Recruitment centers

1

Recruitment center

Name of recruitment center

kerman afzalipour hospital

Full name of responsible person

Dr. KHatereh Mohammadi

Street address

kerman, Imam highway, AfzaliPour Landscape, AfzaliPour Training- Health Center, Adjacent to Bahonar University

City

Kerman

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancellor for Research and Technology of
kerman University of Medical Sciences, Physiology res

Full name of responsible person

Dr.Hamid Najafi pour

Street address

Kerman, Vice chancellor for Research and Technology
of University of Medical Sciences, Physiology research
center, Tahmasb Abad crossroads, the begining of
Jahad Boulevard, the begining of Ebn-e-Sina street, In
front of Besat clinic

City

Kerman

Grant name

Grant code / Reference number

**Is the source of funding the same sponsor
organization/entity?**

Yes

Title of funding source

Vice chancellor for Research and Technology of kerman
University of Medical Sciences, Physiology res

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Kerman afzalipour hospital

Full name of responsible person

Dr. Mojgan Sanjari

Position

Associated professor

Other areas of specialty/work

Street address

Kerman, Imam highway, AfzaliPour Landscape,
AfzaliPour Training- Health Center, Adjacent to
Bahonar University

City

Kerman

Postal code

7616913911

Phone

+98 341322225070

Fax

+98 34 1211 3426

Email

msanjari@kmu.ac.ir

Web page address

<http://www.kmu.ac.ir/sitewizard/admin/wizard/Default.aspx?Pageld=3089>

**Person responsible for scientific
inquiries**

Contact

Name of organization / entity

Kerman hospital afzalipour

Full name of responsible person

Dr. Mojgan Sanjari

Position

Associated professor

Other areas of specialty/work

Street address

Kerman, Imam highway, AfzaliPour Landscape,
AfzaliPour Training- Health Center, Adjacent to
Bahonar University

City

Kerman

Postal code

7616913911

Phone

+98 341322225070

Fax

+98 34 1322 2763

Email

msanjari@kmu.ac.ir

Web page address

<http://www.kmu.ac.ir/sitewizard/admin/wizard/Default.aspx?Pageld=3089>

Person responsible for updating data

Contact

Name of organization / entity

Kerman afzalipour hospital

Full name of responsible person

Dr. Mojgan Sanjari

Position

Associated Professor

Other areas of specialty/work

Street address

Kerman, Imam highway, AfzaliPour Landscape,
AfzaliPour Training- Health Center, Adjacent to
Bahonar University

City

Kerman

Postal code

7616913911

Phone

+98 34 1322 2270

Fax

+98 34 1322 2763

Email

msanjari@kmu.ac.ir

Web page address

<http://www.kmu.ac.ir/sitewizard/admin/wizard/Default.aspx?Pageld=3089>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report

empty
Analytic Code
empty
Data Dictionary
empty